Novartis AG / Speedel Holding AG

Essential Hypertension

Disease Overview

Essential (primary) hypertension is sustained elevation of arterial blood pressure without an identifiable secondary cause and is a leading driver of cardiovascular morbidity and mortality. Roughly half of US adults are affected, and only about 1 in 4 achieve target control on therapy — a treatment gap that motivated the search for novel mechanisms.

Competitive Landscape

When Novartis took out its remaining stake in Speedel in July 2008 for CHF 130/share (~CHF 907M total), the strategic prize was Tekturna/Rasilez (aliskiren) — the first new anti-hypertensive class in more than a decade and the first orally bioavailable direct renin inhibitor, FDA-approved in March 2007. The hypertension market at the time was crowded and largely genericized, dominated by ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan/Diovan, telmisartan/Micardis), beta blockers, calcium channel blockers, and thiazides. Speedel had developed the novel chemical synthesis route, and Novartis sought to consolidate IP and royalty economics ahead of an aggressive 'ASPIRE HIGHER' outcomes program designed to push aliskiren into broader cardiorenal indications. The thesis unraveled: in December 2011, Novartis halted the ALTITUDE trial in diabetic nephropathy after observing increased stroke, hyperkalemia, hypotension, and renal events when aliskiren was combined with ACE/ARB therapy, and FDA added contraindications in 2012. Tekturna never approached blockbuster expectations and was eclipsed by genericized ARBs and combinations like Entresto (sacubitril/valsartan) for HF. The deal is now considered a strategic miss.